Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

被引：4

作者：

Ferraro, Francesca ^{[1
]}

Gruszczynska, Agata

Ruzinova, Marianna B. ^{[1
,2
]}

Miller, Christopher A. ^{[1
]}

Percival, Mary Elizabeth ^{[3
,4
]}

Uy, Geoffrey L. ^{[1
]}

Pusic, Iskra ^{[1
]}

Jacoby, Meagan A. ^{[1
]}

Christopher, Mathew J. ^{[1
]}

Kim, Miriam Y. ^{[1
]}

Westervelt, Peter ^{[1
]}

Cashen, Amanda F. ^{[1
]}

Schroeder, Mark A. ^{[1
]}

DiPersio, John F. ^{[1
]}

Abboud, Camille N. ^{[1
]}

Wartman, Lukas D. ^{[1
]}

Gao, Feng ^{[5
]}

Link, Daniel C. ^{[1
]}

Ley, Timothy J. ^{[1
]}

Welch, John S. ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA

[3] Univ Washington, Div Hematol, Dept Internal Med, Sch Med, Seattle, WA USA

[4] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA

[5] Washington Univ, Div Publ Hlth Sci, Dept Surg, Sch Med, St Louis, MO USA

来源：

HAEMATOLOGICA | 2022年 / 107卷 / 07期

关键词：

TP53; MUTATIONS; IMPACT; AML;

D O I：

10.3324/haematol.2021.280153

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1709 / 1713

页数：5

共 50 条

[1] Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53-Mutated Acute Myeloid Leukemia
Csizmar, Clifford M.
Saliba, Antoine N.
Peterson, Kevin L.
Meng, Xue Wei
Smith, B. Douglas
Ghiaur, Gabriel
Patnaik, Mrinal M.
Kaufmann, Scott H.
BLOOD, 2024, 144 : 5782 - 5783
[2] TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
Testa, Ugo
Castelli, Germana
Pelosi, Elvira
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2023, 15 (01)
[3] Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
Boddu, Prajwal
Kantarjian, Hagop
Ravandi, Farhad
Garcia-Manero, Guillermo
Borthakur, Gautam
Andreeff, Michael
Jabbour, Elias J.
Benton, Christopher B.
DiNardo, Courtney D.
Konopleva, Marina
Daver, Naval
Patel, Keyur
Takahashi, Koichi
Kanagal-Shamanna, Rashmi
Cortes, Jorge
Kadia, Tapan
LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2238 - 2241
[4] Precision medicine for TP53-mutated acute myeloid leukemia
Brattas, Marte Karen
Reikvam, Hakon
Tvedt, Tor Henrik Anderson
Bruserud, Oystein
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (05): : 263 - 274
[5] Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
Vanttinen, Ida
Ruokoranta, Tanja
Saad, Joseph J.
Kytola, Sari
Hellesoy, Monica
Gullaksen, Stein-Erik
Ettala, Pia-Sofia
Pyorala, Marja
Rimpilainen, Johanna
Siitonen, Timo
Wennerberg, Krister
Gjertsen, Bjorn T.
Heckman, Caroline A.
Kontro, Mika
Kuusanmaki, Heikki
BLOOD, 2023, 142
[6] Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
Kong, Jinyu
Chen, Nan
Li, Mengyun
Zhang, Jian
Wu, Xiaoxia
Zong, Lihong
Wu, Depei
Song, Baoquan
Qiu, Huiying
ANNALS OF HEMATOLOGY, 2022, 101 (03) : 697 - 699
[7] Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
Jinyu Kong
Nan Chen
Mengyun Li
Jian Zhang
Xiaoxia Wu
Lihong Zong
Depei Wu
Baoquan Song
Huiying Qiu
Annals of Hematology, 2022, 101 : 697 - 699
[8] TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges
Ghimire, Bipin
Zimmer, Markie
Donthireddy, Vijayalakshmi
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025,
[9] Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.
Shoukier, Mahran
Konopleva, Marina
Dinardo, Courtney Denton
Ravandi, Farhad
Andreeff, Michael
Garcia-Manero, Guillermo
Jabbour, Elias
Daver, Naval Guastad
Borthakur, Gautam
Pemmaraju, Naveen
Montalban-Bravo, Guillermo
Benton, Christopher Brent
Short, Nicholas James
Bhalla, Kapil N.
Cortes, Jorge E.
Kantarjian, Hagop M.
Kadia, Tapan M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Shallis, Rory M.
Bewersdorf, Jan P.
Stahl, Maximilian F.
Halene, Stephanie
Zeidan, Amer M.
CANCERS, 2022, 14 (10)

← 1 2 3 4 5 →